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The first magnetic resonance (MR) scanners for imaging the human body became commercially available in the early 1980s. Early in the development of magnetic resonance imaging (MRI) it was believed that contrast medium would not be necessary because of the good soft-tissue discrimination obtained, but before long it became obvious that contrast agents could provide additional diagnostic information. Currently, up to nine gadolinium-based agents are available in most countries ( Table 1) . Six agents are distributed in the extracellular fluid and are excreted by glomerular filtration. The remaining three agents are so-called organspecific, protein-binding, or high relaxivity agents. The currently available gadolinium-based contrast media are only approved for intravenous injection, not for intra-arterial or intra-cavitary injection. Because MRI has better soft tissue resolution than computed tomography (CT), the extracellular MR contrast agents are on average only used in one-third of the MR examinations whereas iodine-based contrast media are used for around two-thirds of CT examinations. Also the molar dose used for an average MR examination is approximately eight times lower than for CT.
Since gadolinium-based contrast agents were introduced, there have been rapid developments, both in MR techniques and in the use of these agents, which could not have been foreseen when most of the agents were developed and underwent testing (phase I to III trials). In the early 2000s gadolinium-based contrast agents were considered to be one of the safest drugs on the market and were used rather liberally, even in patients with poor renal function. However, like all drugs, gadolinium-based contrast media may cause adverse events. Adverse events are divided into acute (within 60 min the exposure to the contrast agent), late (from 1 h to 7 days), and very late (occurring more than 7 days after the exposure to the agent) (1) . Acute adverse events can be either generalized (systemic) or renal reactions. Generalized reactions may be mild, moderate, or severe. Moderate and severe reactions requiring medical treatment are infrequent (<0.2%) (2) . Renal adverse reactions, often called contrast-induced nephropathy (CIN), are rarely seen after gadoliniumbased contrast media in the doses used for MRI (3) .
In 2006, it became apparent that some gadoliniumbased contrast media were responsible for a very late adverse reaction, nephrogenic systemic fibrosis (NSF) (4, 5) . In North America and Western Europe, NSF appears to have been eliminated by no longer using less stable gadolinium-based contrast agents in patients with reduced renal function, or, in some countries, by not using less stable agents at all. I have not been able to find any reports of NSF in the peer-reviewed literature, where the patient received the agent after 2009; however, the lack of cases in the peer-reviewed literature does not exclude that there are cases (5) . The aim of this review is to bring the reader up to date on this devastating very late adverse reaction, which, up until now, is estimated to have affected around 10,000 patients with reduced renal function since 1997 (6) .
Clinical features of NSF
An idiopathic skin condition characterized by thickening and hardening of the skin of the extremities and sometimes the trunk was first described in California in 1997, but it took another 3 years before this observation and reports from three other centers were published in the peer-reviewed literature (7) . The diagnosis of NSF requires systematic examination of the skin as well as careful light-microscopy of a deep skin biopsy. The NSF registry in New Haven (CT, USA) has proposed a diagnostic scoring system to make this difficult diagnosis easier and ensure similar evaluation/diagnosis worldwide (8) , and their criteria should be used whenever there is any suspicion of NSF.
NSF was initially observed in and thought to affect the skin only, and was called nephrogenic fibrosing dermopathy (NFD). It is now apparent that it may involve organs such as the liver, lungs, muscles, and heart and this involvement probably explains the suspected increased mortality of NSF patients. NSF affects all ages and races. The typical patient has absent or poor renal function (9, 10) .
The first signs of NSF may be seen hours or years after exposure to gadolinium-based contrast agents (11) . In most patients, NSF begins with subacute swelling of the distal extremities, followed in subsequent weeks by severe skin induration, which may extend to involve the thighs, forearms, and lower abdomen (9, 11) . The skin induration may be aggressive and associated with constant pain, muscle restlessness, and loss of skin flexibility ( Fig. 1 ). In some cases, NSF leads to serious physical disability, including becoming wheelchair bound. For many patients, the skin thickening inhibits flexion and extension of joints, resulting in contractures. Severely affected patients may be unable to walk or fully extend the upper and lower limb joints. Complaints of muscle weakness are common, and deep bone pain in the hips and ribs has been described. Radiography may show soft tissue calcification.
There is great variability. NSF severity may be graded from 0 to 4: 0, no symptoms; 1, mild physical, cosmetic, or neuropathic symptoms not causing any kind of disability; 2, moderate physical and/or neuropathic symptoms limiting physical performance to some extent; 3, severe symptoms limiting daily physical activities (walking, bathing, shopping, etc.); and 4, severely disabling symptoms causing dependence on aid or devices for common, daily activities (11) . Patients with grade 0, 1, or 2 disease are rarely included in retrospective studies and this explains the low prevalence in such studies compared to those based on visual inspection of the skin of all patients exposed to a gadolinium-based contrast agent.
In one study it was shown that 18-month mortality of NSF patients was 40% compared to 16% for patients without NSF, with an adjusted hazard ratio of 2.9 (95%CI, 1.3-6.5; P ¼ 0.008) (12) . In 32 patients with nephrogenic systemic fibrosis, 10 died at a median of 112 days after diagnosis (13) . At autopsy (3 patients) there were appreciable amounts of gadolinium, iron, and aluminum, as measured by indirectly coupled plasma-mass spectrometry and confirmed by X-ray fluorescence, in the heart, blood vessels, and skin. In this high-risk group, it is difficult to differentiate deaths caused by complications of the underlying disease and its treatment from those due to NSF. NSF without exposure to a less stable gadolinium-based contrast agent is very unlikely when one looks back on the publications from the last 8 years.
Preclinical indications of gadolinium toxicity
In the early 1980s, MR contrast media were being developed and there was also independent chemical research being conducted on the lanthanides. Research on potential MR contrast media suggested that copper (Cu 2þ ), manganese (Mn 2þ ), and gadolinium (Gd 3þ ) were possible paramagnetic ions for use in MRI (14) . Gadolinium (atomic number 64 and atomic weight of 157) with seven unpaired electrons was the most powerful and had the highest relaxivity per atom of all those tested (15) . Unfortunately, it was also the most toxic of the ions tested. During research on the lanthanides, Evans and Drouven noted that they could cause changes in the collagen structure of skin (16) . They published a textbook about these ions, Biochemistry of Lanthanides, in 1990, just 1 year after the American Food and Drug Administration (FDA) approved the first gadolinium-based contrast agent for intravenous use (17) .
In 1991 a workshop on contrast-enhanced MRI was organized by the Society of Magnetic Resonance in Medicine (now the International Society of Magnetic Resonance in Medicine [ISMRM]). The abstracts and discussions were published in the Journal of the Society of Magnetic Resonance in Medicine, but were not widely read (18) . At this meeting, the stability of non-ionic linear chelated gadolinium agents was much debated. It was noted that pathological changes, which occurred after exposure to a non-ionic linear chelate gadolinium agent, were not seen after exposure to an ionic linear agent. The following year it was decided that a new non-ionic linear chelate, gadopendiamide, should not be brought to the market because of concerns about the safety findings, which were similar to those seen after other non-ionic linear chelates (19) . Three years later, using relaxometry it was shown that gadodiamide releases gadolinium in serum over time (20) ; no other agents were studied. Thirteen years later it was again shown that non-ionic linear agents released much more of the toxic gadolinium ion in serum than did the other agents (21) .
The first major sign of a clinical problem with the stability of the non-ionic linear agents came when Prince et al. in 2003 reported that gadodiamide may cause spurious hypocalcemia (22) . Both gadodiamide and gadoversetamide may interfere with calcium measurement obtained by assays using the ''wet'' method but not the assays using the ''dry'' (23, 24) . The false measurement of serum calcium levels did not occur with gadopentetate dimeglumine or gadoteridol (25) . This was the first clinical sign to the radiological community about stability problems with the non-ionic linear agents, but it was not recognized as such.
Why these various safety concerns did not receive attention outside a small group of experts will never be known, but this failure illustrates the importance of transparency in all aspects of drug development.
Stability of gadolinium-based agents
The various gadolinium-based agents differ in their tendency to release free gadolinium ions. In an ionic linear molecule Gd 3þ is coordinated with five carboxyl groups and three amino nitrogen atoms. The three negatively charged carboxyl groups neutralize the three positive charges of the Gd ion and the remaining two carboxyl groups are neutralized by two meglumine cations. In a non-ionic linear molecule such as gadodiamide or gadoversetamide, the number of carboxyl groups is reduced to three because each of the other two carboxyl groups has been replaced by a non-ionic methyl amide. Although both amide carbonyl groups are directly coordinated to Gd 3þ , the binding is weaker compared to that with the carboxyl groups. This weakens the grip of the non-ionic chelate on the Gd 3þ and decreases the stability of the complex (26) .
The other feature influencing the binding between the Gd 3þ and the chelate is whether the configuration of the molecule is cyclic or linear. The macrocyclic molecule offers better protection and binding of Gd 3þ because it is a pre-organized rigid ring of almost optimal size to cage the gadolinium ion. In contrast, the linear structure, which is a flexible open chain, provides weaker protection of the gadolinium ion. The rates of dissociation of gadolinium from macrocyclic ligands are several orders of magnitude slower than their dissociation from linear chelates (27) .
A large amount of excess chelate is present in agents of low stability. The excess chelate is included in the preparation to ensure the absence of free Gd 3þ in solution. The addition of excess chelate to gadodiamide, a non-ionic linear chelate, dramatically reduces the acute toxicity of non-formulated preparations, which have no excess chelate, by a factor of 2.5 in acute toxicity studies (intravenous LD 50 ) (26, 28) .
Pathophysiology of NSF
Transmetallation of gadolinium-based contrast media leads to release of free gadolinium by replacing the Gd 3þ within the chelate molecule by body cations such as iron, copper, zinc, and calcium. Zinc is the main cation which displaces Gd 3þ , because of its high concentration in the blood (55-125 mmol/L).
The elimination half-life of gadolinium-based contrast agents in patients with normal renal function is around 90 min, but it can be prolonged to 24 h or more in patients with advanced chronic kidney insufficiency (29) . In patients with advanced chronic kidney insufficiency, including those on dialysis, in whom the contrast agent remains in the body for a long time, transmetallation may cause release of free Gd 3þ from gadolinium-based contrast agents (26) . The free Gd 3þ ions become attached to endogenous anions particularly phosphate and form insoluble salts that deposit in tissues. Local macrophages engulf these insoluble molecules and release a range of cytokines, including TGFb1, which attract circulating fibrocytes and initiate the process of fibrosis (26, 30, 31) . The tissue fibrosis in NSF is more likely caused by circulating fibrocytes recruited from the circulation than by proliferation of resident dendritic cells. In the skin and fascia of NSF patients, hybridization studies have showed a marked increase in TGFb1 mRNA levels (9, 32) .
Studies in rats have used a dose of 2.5 mmol/kg dose of gadolinium-based agents, which is not a high dose for rats because they clear the agents from the blood very rapidly. It is considered that this 2.5 mmol/kg dose in rats is equivalent to 0.3 mmol/kg (''triple dose'') in man. Rats with normal renal function were given repeated injections of 2.5 mmol/kg of six different gadolinium-based contrast agents over a 20-day period. Skin lesions consistent with human NSF were seen as early as 8 days after starting non-formulated gadodiamide (without excess chelate) and 20 days after starting formulated gadodiamide (gadodiamide plus the excess chelate caldiamide, the commercial solution), but not when gadopentetate was given (33) . The highest Gd 3þ concentrations in the skin and the most advanced skin lesions were found in animals that received the low stability agents. Skin changes occurred despite the rats' normal renal function. In another rat study, 2.5 mmol/kg of six different gadolinium-based agents was injected. The highest concentrations of gadolinium in skin, liver, and bone occurred with gadodiamide. With gadopentetate, skin gadolinium concentration was 10 times less and with gadoterate and gadobutrol 30 times less (34) . Already by 1992, it was known that gadoterate was superior to gadopentetate, as indicated by an 85% improvement in safety; the ratio of LD 50 to effective dose was 53 for gadoterate versus 28 for gadopentetate (35) . Gadoterate also showed significantly higher stability in serum based on metal retention, with less than 2% of the gadolinium being released after 150 h compared with 10-20% of the gadolinium being released from gadopentetate. Gadolinium may accumulate in tissues other than skin, such as bone and liver, and greater amounts were found after linear than after macrocyclic agents (36) . Retention of gadolinium in bone was greater in renally impaired mice than in mice with normal renal function (37) . Gd 3þ retention in human bone was 2-4 times more with gadodiamide than with the macrocyclic agent gadoteridol in patients with normal renal function (38) . These studies suggest that multiple large doses of low stability gadoliniumbased contrast agents may cause heavy metal toxicity even in patients with normal renal function.
Serum from NSF patients stimulates fibroblast hyaluron synthesis up to seven times and collagen by up to 2.4 times compared to control fibroblast cultures incubated with serum from healthy volunteers and dialysis patients not suffering from NSF. Proliferation of fibroblasts exposed to gadodiamide (1.0 mM) for up to 7 days was stimulated significantly (39) . Gadodiamide has also induced the expression of a-smooth muscle actin staining, suggesting induction of a myofibroblast phenotype. Further studies comparing various gadolinium-based contrast agents are required to show whether they have different effects on fibroblasts. In in vitro studies of human fibroblasts in culture gadodiamide stimulated fibroblast proliferation and collagen production but had no significant effect on keratinocytes. The stable macrocyclic agent meglumine gadoterate had no effect, except at very high (10 mM) concentrations (40) .
The ultrastructural site of gadolinium retention in the skin of rats with impaired renal function given formulated gadodiamide (gadodiamide plus the excess chelate caldiamide) has been evaluated. Gadolinium was detected extracellularly around segments of the collagen fibrils and intracellularly within fragments of collagen fibrils in fibroblasts and in histiocytes (41) . In rats given the same doses of gadoterate, no gadolinium was detected within skin collagen fibrils or fibroblasts and there were no skin changes similar to NSF. Bone, liver, and kidney were also examined and the greatest difference between gadodiamide and gadoterate was in the skin, where the concentration of gadolinium was 40 times greater with gadodiamide than with gadoterate (41) .
To be continued in the next issue of Acta Radiologica.
